London, X0, based Investment company Abingworth LLP (Current Portfolio) buys Vaxcyte Inc, sells Personalis Inc, CRISPR Therapeutics AG during the 3-months ended 2020Q4, according to the most recent filings of the investment company, Abingworth LLP. As of 2020Q4, Abingworth LLP owns 12 stocks with a total value of $235 million. These are the details of the buys and sells.
For the details of Abingworth LLP's stock buys and sells,
go to www.gurufocus.com/guru/abingworth+llp/current-portfolio/portfolio
These are the top 5 holdings of Abingworth LLP
- Vaxcyte Inc (PCVX) - 4,168,718 shares, 47.05% of the total portfolio. New Position
- Phathom Pharmaceuticals Inc (PHAT) - 1,203,135 shares, 16.98% of the total portfolio.
- Soleno Therapeutics Inc (SLNO) - 10,302,602 shares, 8.45% of the total portfolio.
- Verona Pharma PLC (VRNA) - 2,457,499 shares, 7.19% of the total portfolio.
- NuCana PLC (NCNA) - 3,333,333 shares, 6.36% of the total portfolio.
New Purchase: Vaxcyte Inc (PCVX)
Abingworth LLP initiated holding in Vaxcyte Inc. The purchase prices were between $26.57 and $51.74, with an estimated average price of $37.01. The stock is now traded at around $25.440000. The impact to a portfolio due to this purchase was 47.05%. The holding were 4,168,718 shares as of 2020-12-31.
Sold Out: Personalis Inc (PSNL)
Abingworth LLP sold out a holding in Personalis Inc. The sale prices were between $21.84 and $44, with an estimated average price of $30.35.
Sold Out: CRISPR Therapeutics AG (CRSP)
Abingworth LLP sold out a holding in CRISPR Therapeutics AG. The sale prices were between $79.67 and $173.23, with an estimated average price of $118.75.
Here is the complete portfolio of Abingworth LLP. Also check out: